2015
An update on the current pharmacotherapy for endometrial cancer
de Haydu C, Black JD, Schwab CL, English DP, Santin AD. An update on the current pharmacotherapy for endometrial cancer. Expert Opinion On Pharmacotherapy 2015, 17: 489-499. PMID: 26629895, DOI: 10.1517/14656566.2016.1127351.Peer-Reviewed Original ResearchConceptsEndometrial cancerMainstay of treatmentCommon gynecologic malignancyCurrent conventional therapiesGynecologic malignanciesCurrent pharmacotherapyAvailable pharmacotherapiesConventional therapyCurrent therapiesEndometrial tumorsTargeted therapyImmunohistochemical characterizationRadiation therapyClinical careAggressive formNew therapiesPreclinical settingTherapyTherapeutic agentsCancerPharmacotherapyTumorsAvailable literatureHistoric treatmentTreatment
2014
Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer
Acevedo-Gadea C, Santin AD, Higgins SA, Urva S, Ratner E, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Abu-Khalaf MM. Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer. International Journal Of Gynecological Cancer 2014, 24: 528-533. PMID: 24557436, DOI: 10.1097/igc.0000000000000085.Peer-Reviewed Original ResearchConceptsOral topotecanEndometrial cancerDay 1Pelvic external beam radiation therapyMammalian targetExternal beam radiation therapyPhase I clinical trialRecurrent endometrial cancerAdvanced endometrial cancerDose-limiting toxicityEfficacy of topotecanRapamycin inhibitor everolimusBeam radiation therapyOral everolimusStable diseaseVaginal brachytherapyMedian ageRapamycin inhibitorsInhibitor everolimusPreclinical dataClinical trialsMedian numberPharmacokinetic assessmentRadiation therapyEverolimus
2000
Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix
Santin A, Hermonat P, Ravaggi A, Bellone S, Roman J, Pecorelli S, Cannon M, Parham G. Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. International Journal Of Radiation Oncology • Biology • Physics 2000, 48: 997-1006. PMID: 11072156, DOI: 10.1016/s0360-3016(00)00769-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsCisplatinCombined Modality TherapyFemaleHumansImmunity, CellularInterferon-gammaInterleukin-2Killer Cells, NaturalLymphocyte ActivationLymphocyte SubsetsMembrane GlycoproteinsMiddle AgedPerforinPore Forming Cytotoxic ProteinsProspective StudiesReceptors, Interleukin-2Uterine Cervical NeoplasmsConceptsT cellsIL-2Lymphoblast transformationRadiation therapyImmune functionNatural killer cytotoxic activityCD25-positive lymphocytesRadiation-induced immunosuppressionPercentage of CD8Advanced cervical cancerT cell numbersNatural killer cellsT cell subsetsActivation markers CD25C-RTMean absolute numberB cell numbersK562 cellsCisplatinum administrationConcurrent cisplatinumLymphocyte subsetsNK cellsConcurrent administrationKiller cellsUterine cervix
1998
Radiation‐enhanced expression of E6/E7 transforming oncogenes of human papillomavirus‐16 in human cervical carcinoma
Santin A, Hermonat P, Ravaggi A, Chiriva‐Internati M, Pecorelli S, Parham G. Radiation‐enhanced expression of E6/E7 transforming oncogenes of human papillomavirus‐16 in human cervical carcinoma. Cancer 1998, 83: 2346-2352. PMID: 9840534, DOI: 10.1002/(sici)1097-0142(19981201)83:11<2346::aid-cncr14>3.0.co;2-g.Peer-Reviewed Original ResearchConceptsE6/E7 oncoproteinsMHC class ICervical carcinoma cell linesCarcinoma cell linesCervical carcinomaDose-dependent mannerE6/E7High dosesE7 oncoproteinsSiHa cell lineClass IRadiation therapyMajor histocompatibility complex restriction elementCell linesRadiation-induced drug resistanceHigh-risk HPV genotypesHPV-positive cervical carcinoma cell linesTumor cellsE6/E7 oncogenesE7 oncoprotein expressionE7 viral proteinsHuman papillomavirus infectionImportant risk factorTumor rejection antigensHuman papillomavirus 16The effects of irradiation on the expression of a tumour rejection antigen (heat shock protein gp96) in human cervical cancer
Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Hiserodt JC, Batchu RB, Pecorelli S, Parham GP. The effects of irradiation on the expression of a tumour rejection antigen (heat shock protein gp96) in human cervical cancer. International Journal Of Radiation Biology 1998, 73: 699-704. PMID: 9690688, DOI: 10.1080/095530098141951.Peer-Reviewed Original ResearchConceptsTumor rejection antigensHeat shock protein gp96Shock protein gp96Human cervical cancerCervical carcinoma cell linesRejection antigensHigh dosesHuman cervical carcinoma cell lineCervical cancerCarcinoma cell linesTumor cellsMajor histocompatibility complex class ILocal radiation therapyHistocompatibility complex class IBiologic response modifiersCo-stimulation moleculesComplex class ICell linesCervical cancer cellsDose-dependent mannerViral antigensResponse modifiersICAM-1Radiation therapyGp96 mRNA
1996
Effects of Irradiation on the Expression of Surface Antigens in Human Ovarian Cancer
Santin A, Hiserodt J, Fruehauf J, DiSaia P, Pecorelli S, Granger G. Effects of Irradiation on the Expression of Surface Antigens in Human Ovarian Cancer. Gynecologic Oncology 1996, 60: 468-474. PMID: 8774659, DOI: 10.1006/gyno.1996.0075.Peer-Reviewed Original ResearchConceptsMHC class ISurface antigenHER2-neuHigh dosesClass IITumor cellsCell linesClass IICAM-1 antigenHuman ovarian cancerHuman ovarian carcinoma cell linesOvarian carcinoma cell linesCA 125Carcinoma cell linesOvarian cancerICAM-1Radiation therapyIrradiation-induced upregulationImmune recognitionTumor tissueAntigenDosesCellsExposureExpression